| Literature DB >> 27249553 |
Ingeborg H F Herold1, Salvatore Saporito2, Massimo Mischi2, Hans C van Assen2, R Arthur Bouwman3, Anouk G W de Lepper4, Harrie C M van den Bosch5, Hendrikus H M Korsten6, Patrick Houthuizen4.
Abstract
BACKGROUND: Pulmonary transit time (PTT) is an indirect measure of preload and left ventricular function, which can be estimated using the indicator dilution theory by contrast-enhanced ultrasound (CEUS). In this study, we first assessed the accuracy of PTT-CEUS by comparing it with dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). Secondly, we tested the hypothesis that PTT-CEUS correlates with the severity of heart failure, assessed by MRI and N-terminal pro-B-type natriuretic peptide (NT-proBNP). METHODS ANDEntities:
Keywords: B-type natriuretic peptide; cardiac magnetic resonance imaging; contrast echocardiography; heart failure; pulmonary transit time
Year: 2016 PMID: 27249553 PMCID: PMC4989099 DOI: 10.1530/ERP-16-0011
Source DB: PubMed Journal: Echo Res Pract ISSN: 2055-0464
Figure 1Overview of a DCE-MRI (A) and CEUS (B) in one patient. A bolus of gadolinium (A) and UCA, SonoVue 10μLmL−1 (B), passed through the right and left ventricles (RV and LV). ROIs are drawn in the right (blue ROI (A) and red ROI (B)) and left ventricle (green ROI (A) and yellow ROI (B)), and signal or acoustic IDCs are estimated within the ROIs, expressed in panels C and D. The raw IDC (dotted lines) are fitted to the LDRW model (straight lines), and MTT (dashed vertical lines) of the contrast bolus in both ventricles is estimated. The difference in MTT is referred to as the pulmonary transit time. AU, arbitrary units.
Demographics of the subjects (n=20).
| Age (year) | 67±10 |
| Male/female ( | 10/10 |
| BMI (kgm–2) | 28.9±6.2 |
| BSA | 1.9±0.2 |
| QRS (ms) | 160±18 |
| LBBB (n) | 18/20 |
| Non-LBBB ( | 2/20 |
| NYHA functional classes ( | |
| I | 4/20 |
| II | 6/20 |
| III | 10/20 |
| IV | 0 |
| Mitral valve insufficiency ( | 19/20 |
| Mild | 14 |
| Moderate | 3 |
| Severe | 2 |
| Cardiovascular medication | |
| ACEi ( | 15/20 |
| AR blockers (n) | 4/20 |
| Beta blocker ( | 19/20 |
| Aldosteron inhibitor( | 6/20 |
| Diuretic ( | 11/20 |
| Echocardiographic parameters | |
| LVEDV index (mLm–2) | 120±41 |
| LVESV index (mLm–2) | 82±38 |
| EF (%) | 35±11 |
| IVWD (ms) | 48±31 |
| SPWMD (ms) | 294±117 |
| MRI parameters | |
| LVEDV index (mL m–2) | 137±42 |
| LVESV index (mL m–2) | 97±42 |
| EF (%) | 32±13 |
| fSV (mL) | 68±13 |
| Laboratory parameter | |
| NT-proBNP (pmol L–1)* | 188±216 |
Results are presented as mean±s.d. or as absolute numbers. ACE, angiotensin-converting enzyme inhibitor; AR, angiotensin-II receptor antagonist; BMI, body mass index; BSA, body surface area according to the Dubois & Dubois equation; EF, ejection fraction; fSV, forward stroke volume; IVMD, interventricular mechanical delay; LBBB, left bundle branch block; LVEDV, left ventricular end-diastolic volume ; LVESV, left ventricular end-systolic volume; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association Classification; SPWMD, septal-to-posterior wall motion delay; asterisk indicates 18 patients.
Figure 2The correlation between PTT-MRI and mean PTT-CEUS of three measurements by CEUS (A). Correlation between both techniques for nPTT (B). The dotted lines indicate the 95% CIs.
Figure 3Bland–Altman analysis of PTT-CEUS and PTT-MRI (A). Solid line is the mean difference (bias); dashed lines are the limits of agreement (1.96 s.d.). Bland–Altman analysis of nPTT-CEUS and nPTT-MRI (B).
Correlation of (n)PTT with volumes measured by MRI and NT-proBNP.
| LVEDVMRI (mLm−2) | 0.46 | 0.58 | 0.45 | 0.65 |
| LVESVMRI (mLm−2) | 0.45 | 0.58 | 0.50 | 0.70 |
| SVMRI (mL) | 0.12 | 0.07 | -0.16 | −0.15 |
| fSVMRI (mL) | −0.06 | −0.34 | −0.07 | −0.44 |
| EFMRI (%) | −0.44 | −0.52 | −0.61 | −0.71 |
| NT-proBNP (pmolL−1) | 0.54* | 0.68* | 0.64* | 0.79* |
Correlation expressed as Pearson’s r of pulmonary transit time (PTT) measurements by contrast-enhanced ultrasound (CEUS) and dynamic contrast-enhanced MRI (DCE-MRI) with left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), stroke volume (SV), forward stroke volume (fSV) measured by phase-contrast MR angiography in 19 patients, ejection fraction (EF), and NT-proBNP (18 measurements). Asterisk indicates Spearman’s ρ.
Figure 4Correlations of nPTT by CEUS and left ventricular end-diastolic volume (LVEDV) index (A), left ventricular end-systolic volume (LVESV) index (B), stroke volume (SV) nonsignificant (C), ejection fraction (EF) (D), and NT-proBNP (E), and correlation of nPTT by DCE-MRI with NT-proBNP (F). Dotted lines represent 95% CI for the predicted values.
Correlation of (n)PTT with different echocardiographic parameters that could influence PTT.
| Left ventricular parameters | ||
| MR gradient | 0.21 | 0.44 |
| LA size (mL m–2) | 0.50 | 0.50 |
| MV | 0.55* | 0.69* |
| TDI | 0.46* | 0.69* |
| Right ventricular parameters | ||
| TAPSE (mm) | −0.32 | −0.08 P=0.743 |
| TR max velocity (cm s–1) | 0.69 | 0.47 |
Correlation expressed as Pearson’s r of mitral regurgitation (MR), left atrium (LA), early and late diastolic Doppler flow ratio across the mitral valve (MV E/A), tissue Doppler imaging E/e′ (TDI E/e′), tricuspid annular plane systolic elevation (TAPSE), and tricuspid regurgitation (TR). Asterisk indicates Spearman’s ρ.